局所麻酔薬の世界市場:麻酔薬の種類および用途別分析 - 成長、動向および予測

Local Anesthesia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 127 Pages | 納期: 2-3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
局所麻酔薬の世界市場:麻酔薬の種類および用途別分析 - 成長、動向および予測
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 127 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次





第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入者の脅威
    • 代替製品とサービスの脅威
    • 業界内の競争優位

第6章 成長要因、阻害要因、機会、課題の分析(DROC)

  • 市場の成長要因
    • 外科医の増加
    • 麻酔薬の新しい承認
    • 美容整形手術の増加
  • 市場の阻害要因
    • 麻酔薬の副作用の危険性
    • 政府別規制上の問題
  • 機会
  • 主な課題
    • 市場セグメンテーション
    • その他の局所麻酔

第7章 地域別セグメンテーション

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ地域
  • 南米

第8章 競合情勢

  • M&A分析
  • 合意、協業および提携
  • 新製品の発売

第9章 企業プロファイル


第10章 市場の将来展望

Product Code: 46482

The global local anesthesia drugs market was valued at USD 2,526.86 million in 2020, and it is expected to reach USD 3,378.43 million by 2026, registering a CAGR of 4.91% during the forecast period.

The use of local anesthesia in treating patients infected with COVID-19 is in high demand due to its benefits and minimal risk of viral transmission. Additionally, the research article published in the European Archives of Oto-Rhino-Laryngology in 2020 revealed that the topical oropharyngeal lignocaine application significantly increased comfort levels for the patient during oropharyngeal sampling for COVID-19 and had no effect on the detection of SARS-CoV-2 in the upper airway. Thus, the study suggested that topical oropharyngeal lignocaine should be considered as a measure to reduce the viral inoculum sampling of a COVID-19 suspect.

The growth of the global local anesthesia drugs market is driven by various factors, such as the rising number of surgeries requiring local anesthesia, increasing product approvals, and the growing usage of local anesthetic for postoperative pain.

According to the United Nations World Ageing 2019 report, there were around 703 million people aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. Globally, the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. The geriatric population is prone to chronic diseases that lead to organ function failures, as there are changes in the pharmacokinetics and pharmacodynamics related to age and organ function. This factor is expected to increase the number of surgeries, which will drive the growth of the studied market.

Furthermore, the development and approvals of novel local anesthesia drugs prove to be a new revenue-generating resource for the companies in the market. For instance, in February 2021, PainPass launched the first Cannabidiol (CBD)/lidocaine product line that specifically targets those with chronic pain and numbing of muscles externally.

Additionally, the increased funding for the research and development of novel drugs by the pharma companies is also expected to drive market growth. For instance, members of the Pharmaceutical Research and Manufacturers of America (PhRMA) invested USD 83 billion in R&D in 2019, establishing the biopharmaceutical sector as the most R&D-intensive industry in the US economy.

The growing research on local anesthetics is also boosting the market growth. Istituti Ospitalieri di Cremona, Italy, started a clinical trial in 2017, in order to compare the effectiveness of blind local anesthetic infiltration with ultrasound-guided transversals fascia block and spinal anesthesia in patients undergoing inguinal hernia repair surgery. The results of the research are yet to be published. However, the side effects of these drugs and strict regulatory framework are expected to restrain the market studied.

Key Market Trends

Bupivacaine is Expected to Register a Significant Growth in the Forecast Years

Bupivacaine is a prescription medication used as a local anesthetic that blocks the nerve impulses that send pain signals to the brain. This injection is a very useful anesthetic for local and regional anesthesia for several procedures, such as surgery and diagnostic, therapeutic, and obstetrical procedures. It is used in various surgical procedures.

Although all local anesthetics cause changes in the cardiac and central nervous system functions, in the case of Bupivacaine, when injected intravascularly into toxic blood concentrations, it can cause an atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in death.

Pacira Pharmaceuticals Inc. is one of the growing companies recognized for its drug Exparel globally. LGM Pharma, Pfizer, Sagent Pharmaceuticals Inc., and BOC Sciences are the key players globally. In March 2021, the US Food and Drug Administration (FDA) approved the submission of supplemental new drug application (sNDA) submitted by Pacira BioSciences Inc. for the expanded use of its Exparel (Bupivacaine Liposome Injectable Suspension) in pediatric patients. However, Bupivacaine is widely used as local anesthesia due to its efficacy in numbing certain organs. Hence, the rising number of surgeries leads to the high demand for local anesthesia drugs, and it is expected to propel the growth of the market.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the local anesthesia drugs market and is expected to continue its stronghold in the market. The North American anesthesia market is the largest regional market in the world. The market is mainly driven by factors, such as the increasing number of surgeries, the rising aging population with increasing chronic conditions, and advancements in anesthesia technologies.

For instance, according to the American Society of Plastic Surgeons (ASPS), in 2020, about 2,314,720 cosmetic surgical procedures were performed in the United States, as compared to 1,901,049 procedures in 2000. There has been a 22% increase in the adoption rate of these surgical procedures, within a decade. These statistics clearly indicate that surgical procedures are constantly increasing in the region.

As per the Canadian Institute for Health Information (CIHI), around 104,349 Caesarean section deliveries, 70,215 knee replacement surgeries, 55,294 fracture rectifications, 42,449 coronary artery angioplasties, and 58,333 hip replacement surgeries were performed in the country during 2017-2018. These statistics indicate that the demand for local anesthesia is expected to be high in the near future

In addition, several companies are focusing on new product launches and seeking product approvals in Canada. For instance, in December 2019, Heron Therapeutics Inc., a commercial-stage biotechnology company, was granted a review status and accepted by Health Canada for its new drug submission (NDS) for HTX-011, an investigational dual-acting, fixed-dose combination of the local anesthetic called Bupivacaine, along with a low dose of the nonsteroidal anti-inflammatory drug, Meloxicam, for the management of post-operative pain.

Competitive Landscape

The Local Anesthesia Drugs market is competitive and many of the global players are in the market. Companies are focusing on major collaborations, mergers, and acquisitions in order to enhance their market share. Market players are also focusing on R&D to improve product quality and minimize manufacturing costs, developing novel products to improve patient compliance and safety.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definiton
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Surgeries
    • 4.2.2 New Approval of Anesthetic Drugs
    • 4.2.3 Growing Use of Local Anesthetic in Post-operative Pain
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Anesthetic Drugs
    • 4.3.2 Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drug Type
    • 5.1.1 Bupivacaine
    • 5.1.2 Lidocaine
    • 5.1.3 Benzocaine
    • 5.1.4 Ropivacaine
    • 5.1.5 Prilocaine
    • 5.1.6 Chloroprocaine
    • 5.1.7 Others
  • 5.2 By Mode of Administration
    • 5.2.1 Injectable
    • 5.2.2 Surface Anesthetic
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Fresenius SE & Co. KGaA
    • 6.1.3 Glenmark Pharmaceutical Inc.
    • 6.1.4 Mylan N.V.
    • 6.1.5 Pacira Pharmaceuticals, Inc.
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Septodont
    • 6.1.8 Teva Pharmaceutical Industries Ltd